In a report released today, Jailendra Singh from Truist Financial reiterated a Buy rating on Phreesia (PHR – Research Report). The company’s shares closed yesterday at $24.09.
According to TipRanks, Singh is an analyst with an average return of -12.0% and a 38.24% success rate. Singh covers the Healthcare sector, focusing on stocks such as R1 RCM, Icon, and IQVIA Holdings.
Currently, the analyst consensus on Phreesia is a Strong Buy with an average price target of $28.20, which is a 17.06% upside from current levels. In a report released today, JMP Securities also maintained a Buy rating on the stock with a $28.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
PHR market cap is currently $1.38B and has a P/E ratio of -8.97.
Based on the recent corporate insider activity of 125 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PHR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Phreesia (PHR) Company Description:
Phreesia, Inc. provides patient check-in solutions for medical practices. It provides solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform the company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and a payments solution for secure processing of patient payments. Its platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. Phreesia was founded by Chaim Indig and Evan Roberts in January 2005 and is headquartered in New York, NY.
Read More on PHR:
